-- Echo IQ（ASX：EIQ）週四向澳洲證券交易所提交的文件顯示，截至3月31日的三個月內，其用於評估嚴重主動脈瓣狹窄（一種進行性心臟疾病）的決策支援軟體EchoSolv AS的使用量環比增長約131%。 該公司表示，第一季共處理了9,220份超音波心動圖，而2025年12月季度的數據為3,992份。 該公司正在推進其心臟衰竭臨床決策支援產品EchoSolv HF通過美國食品藥物管理局（FDA）的510(k)審批途徑。 根據提交的文件，該公司還致力於與美國大型醫院集團達成合作協議，並推動其產品獲得澳洲藥品管理局（TGA）的監管批准。 週四，Echo IQ的股價下跌了近2%。
Related Articles
International
Saudi Arabia's Quarterly GDP Down 1.5% in Q1, Flash Data Shows
Saudi Arabia's seasonally adjusted real gross domestic product decreased 1.5% on a quarterly basis in the first quarter, compared with a 1.4% rise in the prior three-month period, flash data from the General Authority for Statistics showed Thursday.Annually, the Saudi Arabian economy grew 2.8% during the three-month period, after a 5% increase in the previous quarter.
$^TASI
Asia
Diagens Biotechnology's 2025 Loss Widens
Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.
$HKG:2526
Asia
Daqin Railway Q1 Profit Down 7%; Shares Slip 3%
Daqin Railway Co (SHA:601006) posted first-quarter attributable net profit of 2.38 billion yuan, down 6.9% from 2.56 billion yuan the previous year.Earnings per share slid to 0.12 yuan from 0.13 yuan, according to a Thursday filing with the Shanghai bourse.Operating revenue climbed 4.3% year over year to 18.6 billion yuan from 17.8 billion yuan.Shares of the railway operator declined 3% in recent trade.
$SHA:601006